Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission

Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission

Bibliographic Details
Main Authors:	Lichtenstein, Gary R., Gordon, Glenn L., Zakko, Salam, Murthy, Uma, Sedghi, Shahriar, Pruitt, Ron, Barrett, Andrew C., Bortey, Enoch, Paterson, Craig, Forbes, William P.
Format:	Online
Language:	English
Published:	Springer US 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700064/

Similar Items

Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
by: Oliveira, Lilliana, et al.
Published: (2011)

Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis
by: Rubin, David T., et al.
Published: (2015)

Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis
by: Bajaj, J S, et al.
Published: (2015)

Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease
by: Doherty, Glen A, et al.
Published: (2009)

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine
by: Nanda, Kavinderjit, et al.
Published: (2012)

Genetic variants in cellular transport do not affect mesalamine response in ulcerative colitis.
by: Christopher J Moran, et al.

Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain
by: Webster, Lynn R, et al.
Published: (2015)

Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications
by: Richter, James M., et al.
Published: (2016)

Mesalamine-Induced Myocarditis and Coronary Vasculitis in a Pediatric Ulcerative Colitis Patient: A Case Report
by: Perez-Colon, Elimarys, et al.
Published: (2011)

Exacerbation of Bloody Diarrhea as a Side Effect of Mesalamine Treatment of Active Ulcerative Colitis
by: Shimodate, Yuichi, et al.
Published: (2011)

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine. [Corrigendum]
by: Nanda, K, et al.
Published: (2013)

Effect of Mesalamine and Prednisolone on TNBS Experimental Colitis, following Various Doses of Orally Administered Iron
by: Triantafillidis, John K., et al.
Published: (2014)

Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis
by: Cuffari, Carmen, et al.
Published: (2016)

High- and Low-Dose Oral Delayed-Release Mesalamine in Children With Mild-to-Moderately Active Ulcerative Colitis
by: Winter, Harland S., et al.
Published: (2014)

Complete Remission of Generalized Myasthenia Gravis by Corticosteroid Treatment Alone without Thymectomy
by: Kataoka, Hiroshi, et al.
Published: (2011)

Complete Long-Term Remission of an Inflammatory Pseudotumor under Corticosteroid Therapy
by: Pfeifer, Lukas, et al.
Published: (2011)

The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX® formulated delayed-release mesalamine
by: Yarlas, Aaron, et al.
Published: (2014)

Intrahepatic cholestasis in Bruton's agammaglobulinemia receiving mesalamine for co-morbid Crohn's disease
by: Actis, Giovanni Clemente, et al.
Published: (2014)

Posterior reversible encephalopathy syndrome with PLEDs-plus due to mesalamine
by: Cherian, Ajith, et al.
Published: (2014)

Red-Brown Urine Discolouration in Two Patients Taking Mesalamine
by: Smeets, Tim, et al.
Published: (2016)

Dissolution of Commercially Available Mesalamine Formulations at Various pH Levels
by: Tenjarla, Srini
Published: (2015)

Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis
by: Lichtenstein, Gary R., et al.
Published: (2015)

Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials
by: Pierce, David, et al.
Published: (2014)

Fulminant Amebic Colitis after Corticosteroid Therapy: A Systematic Review
by: Shirley, Debbie-Ann, et al.
Published: (2016)

Corticosteroids in the Treatment of Pseudomembranous Colitis: A Report of 3 Cases
by: Sykes, Ella, et al.
Published: (2012)

Efficacy of Combined Mesalazine Plus Corticosteroid Enemas for Diversion Colitis after Subtotal Colectomy for Ulcerative Colitis
by: Matsumoto, Satohiro, et al.
Published: (2016)

Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis
by: Lichtenstein, Gary R.
Published: (2015)

Corticosteroid in the Treatment of Moderate to Severe Thrombocytopenia Due to Leptospirosis
by: Alian, Shahriar, et al.
Published: (2014)

Histological Remission during Corticosteroid Therapy of Overlapping Nonalcoholic Steatohepatitis and Autoimmune Hepatitis: Case Report and Literature Review
by: Fukuda, Shinichiroh, et al.
Published: (2011)

PReS-FINAL-2167: What is the potential of intra-articular corticosteroid injections to induce sustained remission in children with juvenile idiopathic arthritis?
by: Lanni, S, et al.
Published: (2013)

Lymphocytic Interstitial Pneumonitis Associated with Epstein-Barr virus in Systemic Lupus Erythematosus and Sjögren’s Syndrome.: Complete remission with corticosteroid and cyclophosphamide
by: Yum, Ho-Kee, et al.
Published: (2002)

Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study
by: Mary Kaye Willian, et al.
Published: (2018-04-01)

Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study
by: Suzuki, Yasuo, et al.
Published: (2016)

In vitro controlled release of colon targeted mesalamine from compritol ATO 888 based matrix tablets using factorial design
by: Patel, J.K., et al.
Published: (2009)

Nephrotic syndrome after treatment of Crohn's disease with mesalamine: Case report and literature review
by: Firwana, Belal M., et al.
Published: (2012)

Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1
by: Khare, Vineeta, et al.
Published: (2013)

Modulation of N-glycosylation by mesalamine facilitates membranous E-cadherin expression in colon epithelial cells☆
by: Khare, Vineeta, et al.
Published: (2014)

OPTIMIZATION AND IN VIVO EVALUATION OF MESALAMINE pH DEPENDENT COATED PELLETS FOR PROMISING ILEOCECAL TARGETING
by: Hemant H Gangurde, et al.
Published: (2013-10-01)

Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels
by: Abinusawa, Adeyinka, et al.
Published: (2015)

The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial
by: Somsouk, Ma, et al.
Published: (2014)